Bridge Biotherapeutics, Inc.
10
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.0%
3 terminated/withdrawn out of 10 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Role: lead
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Role: lead
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Role: lead
Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Role: lead
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis
Role: lead
Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Role: lead
First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers
Role: lead
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Role: lead
Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male
Role: lead
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
Role: lead
All 10 trials loaded